doi:10.1159/000538131

[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660.

[2]

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. doi: 10.1053/j.gastro.2007.04.061.

[3]

Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153(4):910–23. doi: 10.1053/j.gastro.2017.08.018.

[4]

Momin BR, Pinheiro PS, Carreira H, Li C, Weir HK. Liver cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):5059–78. doi: 10.1002/cncr.30820.

[5]

Yeh CC, Lin JT, Jeng LB, Ho HJ, Yang HR, Wu MS, et al. Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study. Ann Surg. 2015;261(3):521–6. doi: 10.1097/SLA.0000000000000746.

[6]

Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104(23):1808–14. doi: 10.1093/jnci/djs452.

[7]

Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol. 2015;230(6):1401. doi: 10.1002/jcp.24869.

[8]

Zang S, Ma X, Wu Y, Liu W, Cheng H, Li J, et al. PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma. Hum Pathol. 2017;63:120–7. doi: 10.1016/j.humpath.2017.02.018.

[9]

Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004;334(2):266–75. doi: 10.1016/j.ab.2004.08.019.

[10]

Jara-Gutiérrez Á, Baladrón V. The role of prostaglandins in different types of cancer. Cells. 2021;10(6):1487. doi: 10.3390/cells10061487.

[11]

Gomes RN, Felipe da Costa S, Colquhoun A. Eicosanoids and cancer. Clinics. 2018;73(Suppl 1):e530s. doi: 10.6061/clinics/2018/e530s.

[12]

Dai DF, Swanson PE, Krieger EV, Liou IW, Carithers RL, Yeh MM. Congestive hepatic fibrosis score: a novel histologic assessment of clinical severity. Mod Pathol. 2014;27(12):1552–8. doi: 10.1038/modpathol.2014.79.

[13]

Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, et al. MiR-31-5p-ACOX1 Axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics. 2018;8(2):486–504. doi: 10.7150/thno.22059.

[14]

Cui Y, Shu XO, Li HL, Yang G, Wen W, Gao YT, et al. Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. Int J Cancer. 2017;141(12):2423–9. doi: 10.1002/ijc.31007.

[15]

Johnson J, Schmidt C, Shrubsole M, Billheimer D, Joshi P, Morrow J, et al. Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006;4(11):1358–65. doi: 10.1016/j.cgh.2006.07.015.

[16]

Castro-Sanchez L, Agra N, Llorente Izquierdo C, Motino O, Casado M, Bosca L, et al. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma. Int J Biochem Cell Biol. 2013;45(11):2501–11. doi: 10.1016/j.biocel.2013.08.005.

[17]

Tanaka J, Malchesky PS, Omokawa S, Goldcamp JB, Harasaki H, Vogt DP, et al. Effects of prostaglandin I2, superoxide dismutase, and catalase on ischemia-reperfusion injury in liver transplantation. ASAIO Trans. 1990;36(3):M600–3.

[18]

Zardi EM, Vespasiani Gentilucci U, Picardi A, Ambrosino G, Fazio VM, Dobrina A, et al. Iloprost: an adjunctive approach to chronic viral hepatitis treatment. Med Hypotheses. 2005;64(1):46–52. doi: 10.1016/j.mehy.2004.05.017.

[19]

Schwalke MA, Tzanakakis GN, Vezeridis MP. Effects of prostacyclin on hepatic metastases from human pancreatic cancer in the nude mouse. J Surg Res. 1990;49(2):164–7. doi: 10.1016/0022-4804(90)90256-2.

[20]

Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002;62(1):63–6.

[21]

Moussa O, Yordy JS, Abol-Enein H, Sinha D, Bissada NK, Halushka PV, et al. Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res. 2005;65(24):11581–7. doi: 10.1158/0008-5472.CAN-05-1622.

[22]

Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, et al. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun. 2000;267(1):245–51. doi: 10.1006/bbrc.1999.1840.

[23]

Yokoyama I, Hayashi S, Kobayashi T, Negita M, Yasutomi M, Uchida K, et al. Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Res Exp Med. 1995;195(4):209–15. doi: 10.1007/BF02576790.

[24]

Yokoyama Y, Nimura Y, Nagino M, Bland KI, Chaudry IH. Role of thromboxane in producing hepatic injury during hepatic stress. Arch Surg. 2005;140(8):801–7. doi: 10.1001/archsurg.140.8.801.

[25]

Laffi G, Cinotti S, Filimberti E, Ciabattoni G, Caporale R, Marra F, et al. Defective aggregation in cirrhosis is independent of in vivo platelet activation. J Hepatol. 1996;24(4):436–43. doi: 10.1016/s0168-8278(96)80164-4.

[26]

Ferro D, Basili S, Iuliano L, Camastra C, Giammarresi C, Santarone S, et al. Increased thromboxane metabolites excretion in liver cirrhosis. Thromb Haemost. 1998;79(4):747–51. doi: 10.1055/s-0037-1615058.

[27]

Chavarría ME, Lara-González L, González-Gleason A, García-Paleta Y, Vital-Reyes VS, Reyes A. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol. 2003;188(4):986–92. doi: 10.1067/mob.2003.203.

[28]

Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PLoS One. 2010;5(2):e9340. doi: 10.1371/journal.pone.0009340.

[29]

Vergote IB, van Dam PA, Laekeman GM, Keersmaeckers GH, Uyttenbroeck FL, Herman AG. Prostacyclin/thromboxane ratio in human breast cancer. Tumour Biol. 1991;12(5):261–6. doi: 10.1159/000217713.

[30]

Signorello LB, Hargreaves MK, Blot WJ. The southern community cohort study: investigating health disparities. J Health Care Poor Underserved. 2010;21(1 Suppl):26–37. doi: 10.1353/hpu.0.0245.

[31]

Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, et al. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res. 2013;6(7):646–55. doi: 10.1158/1940-6207.CAPR-13-0083.

[32]

Drew DA, Schuck MM, Magicheva-Gupta MV, Stewart KO, Gilpin KK, Miller P, et al. Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: a randomized clinical trial. Cancer Prev Res. 2020;13(10):877–88. doi: 10.1158/1940-6207.CAPR-20-0216.

[33]

Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, et al. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. Gastroenterology. 2013;145(3):658–67.e11. doi: 10.1053/j.gastro.2013.05.014.

[34]

Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64(23):8613–9. doi: 10.1158/0008-5472.CAN-04-2078.

[35]

Ferroni P, Santilli F, Cavaliere F, Simeone P, Costarelli L, Liani R, et al. Oxidant stress as a major determinant of platelet activation in invasive breast cancer. Int J Cancer. 2017;140(3):696–704. doi: 10.1002/ijc.30488.

[36]

Sciulli MG, Filabozzi P, Tacconelli S, Padovano R, Ricciotti E, Capone ML, et al. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids. 2005;72(2):79–83. doi: 10.1016/j.plefa.2004.10.006.

[37]

Kij A, Kus K, Smeda M, Zakrzewska A, Proniewski B, Matyjaszczyk K, et al. Differential effects of nitric oxide deficiency on primary tumour growth, pulmonary metastasis and prostacyclin/thromboxane A(2) balance in orthotopic and intravenous murine models of 4T1 breast cancer. J Physiol Pharmacol. 2018;69(6). doi: 10.26402/jpp.2018.6.05.

[38]

Aitokallio-Tallberg A. Prostacyclin and thromboxane synthesis by endometrial cancer and leiomyomas. Prostaglandins. 1990;39(3):259–66. doi: 10.1016/0090-6980(90)90045-w.

[39]

Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol. 2005;18(2):221–7. doi: 10.1038/modpathol.3800285.

[40]

Altobelli E, Angeletti PM, Latella G. Role of urinary biomarkers in the diagnosis of adenoma and colorectal cancer: a systematic Review and meta-analysis. J Cancer. 2016;7(14):1984–2004. doi: 10.7150/jca.16244.

[41]

Kim S, Taylor JA, Milne GL, Sandler DP. Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev Res. 2013;6(6):511–8.

doi: 10.1158/1940-6207.CAPR-13-0040

[42]

Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res. 2005;11(16):6087–93. doi: 10.1158/1078-0432.CCR-05-0733.

[43]

Green K. Metabolism of prostaglandin E2 in the rat. Biochemistry. 1971;10(6):1072–86. doi: 10.1021/bi00782a022.

[44]

Yuan JM, Grouls M, Carmella SG, Wang R, Heskin A, Jiang Y, et al. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis. 2019;40(8):989–97. doi: 10.1093/carcin/bgy180.